Inventiva
50 rue de Dijon
Daix
21121
France
Tel: 33-3-80-44-75-00
Website: http://www.inventivapharma.com/
Email: info@inventivapharma.com
About Inventiva
Inventiva is a biopharmaceutical company with several drug candidates at clinical and preclinical stage whose objective is to develop and provide patients with new therapies. The focus of the company’s research and developmentdepartment targets three promising areas, namely fibrotic diseases, the treatment of certain forms of lysosomal diseases and oncology with a priority for the development of indications for orphan diseases for which the unmet medical need and the regulations in force allow an accelerated development.YEAR FOUNDED:
2011
LEADERSHIP:
Founder and CEO: Frédéric Cren
Founder and CSO: Pierre Broqua
CFO: Jean Volatier
CMO: Jean-Louis Abitbol
JOBS:
Please click here for Inventiva job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
FOLLOW INVENTIVA:
Tweets by Inventiva Pharma
103 articles about Inventiva
-
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
4/3/2024
Inventiva announced that it had filed its 2023 Universal Registration Document for the year ended December 31, 2023, including the management report and the annual financial report, with the French “Autorité des Marchés Financiers” and its 2023 Annual Report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission.
-
Inventiva announces the nomination of Andre Turenne as Director
3/28/2024
Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis, also known as non-alcoholic steatohepatitis and other diseases with significant unmet medical needs, announced the nomination of Andre Turenne to its Board of Directors.
-
Inventiva reports its 2023 full-year results
3/27/2024
Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today reported its full-year results for 2023.
-
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results
3/22/2024
Inventiva (Euronext Paris and Nasdaq: IVA) today announced that its management team will host a webcast to present the Company’s 2023 full-year financial results on Thursday, March 28, 2024.
-
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
3/13/2024
Inventiva will hold an investor conference on Tuesday, March 19, to share the results of the LEGEND Phase II trial, a placebo-controlled, study evaluating lanifibranor alone and in combination with the SGLT2 inhibitor empagliflozin in patients with MASH/NASH and type 2 diabetes.
-
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed
3/7/2024
Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”) today announced that it has lifted the previously disclosed1 voluntary pause on screening and randomization of its NATiV3 clinical trial and that sites are resuming screening activities.
-
Following a patient case of severe liver enzyme elevations, Inventiva is suspending its Phase III NATiV3 study in non-alcoholic steatohepatitis as Madrigal Pharmaceuticals awaits a March 14 PDUFA date.
-
Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3
2/15/2024
Inventiva reported certain preliminary unaudited financial results as of and for the full year ended December 31, 2023, including cash, cash equivalents, and revenues, and provided an update on its clinical trial NATiV3.
-
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
1/24/2024
Inventiva announced the half-year report of its liquidity contract with Kepler Cheuvreux.
-
Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank
1/10/2024
Inventiva announced the drawdown of the second tranche of €25 million of the unsecured loan agreement executed with the European Investment Bank on May 16, 2022 with a maturity date on or about January 18, 2027.
-
Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program
12/20/2023
Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”) today announced that the first patient has been randomized in China in the global NATiV3 Phase III clinical trial and provided an update on its clinical development program.
-
Inventiva reports 2023 Third Quarter Financial Information¹
11/21/2023
Inventiva reported financial information for the nine months ended September 30, 2023.
-
Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023
11/6/2023
Inventiva announced that the phase II trial led by Dr. Cusi in patients with type two diabetes has been accepted as late breaker, at the upcoming The Liver Meeting® 2023 hosted by the American Association for the Study of Liver Diseases on November 10-14, 2023 in Boston.
-
Inventiva reports its 2023 first-half financial results and provides a corporate update
9/28/2023
Inventiva reported its financial results for the six months ended June 30, 2023, and provided a corporate update.
-
Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificates
8/31/2023
Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis and other diseases with significant unmet medical needs, announced an approximately €35.7 million financing.
-
Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update
7/27/2023
Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis and other diseases with significant unmet medical needs, reported certain preliminary financial results for the first half of 2023, including its cash, cash equivalents, and revenues, and provided a corporate update.
-
Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update
7/27/2023
Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis and other diseases with significant unmet medical needs, reported certain preliminary financial results for the first half of 2023, including its cash, cash equivalents, and revenues, and provided a corporate update.
-
Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association
6/24/2023
Inventiva announced that the abstract “Lanifibranor Improves Markers of Cardiometabolic Health in Patients with NASH and Type 2 Diabetes, Correlated With Responses in Adiponectin Levels” has been selected for poster presentation during the American Diabetes Association’s 83rd Scientific Sessions taking place on June 23-26, 202 in San Diego, United States.
-
Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD
6/13/2023
Inventiva (Euronext Paris and Nasdaq: IVA) today announced positive topline results of the clinical study conducted by Dr. Kenneth Cusi from the University of Florida, evaluating lanifibranor in patients with NAFLD and type 2 diabetes mellitus (T2D).
-
Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients
6/8/2023
Inventiva and Echosens announce their collaboration in raising awareness about NASH and increase access to screening for patients at risk of developing NASH.